FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1

Microvascular Tissue Marketing Unapproved New Drug

FDA warns San Diego, CA-based Microvascular Tissue about CGMP violations in its production and marketing of an unapproved new drug that is also an unl...

latest-news-card-1
FDA General

FDA Commissioner Defends Vaccine Stance, Transparency Push

In a recent interview, FDA commissioner Marty Makary positions himself as a supporter of vaccines while defending recent agency actions that have draw...

Biologics

Makary Says No Plans for Covid Vaccine Boxed Warning

FDA commissioner Marty Makary says the agency has no plans to add a Black Box Warning to Covid vaccines, contradicting a report from last week saying ...

latest-news-card-1
Human Drugs

3D Imaging CGMP and Listing Violations

FDA warns Little Rock, AR-based 3D Imaging Drug Design and Development about CGMP and listing violations in its production of positron emission tomogr...

latest-news-card-1
Human Drugs

FDA Extends Review Timeline for Aldeyras Dry Eye Drug

FDA extends the review of Aldeyra Therapeutics NDA resubmission for reproxalap, pushing back a regulatory decision on the investigational dry eye dise...

latest-news-card-1

Guide to Increase Female Enrollment in Trials

FDA publishes a draft guidance aimed at increasing the enrollment of females in clinical trials of drugs and medical devices.

latest-news-card-1
Human Drugs

Trump Taps Controversial Figure to Lead Cancer Panel

President Trump appoints Yale epidemiologist Harvey Risch to chair the Presidents Cancer Panel, a move that is raising alarm among cancer researchers ...

latest-news-card-1
Human Drugs

7 Observations on ProRx FDA-483

FDA releases the form FDA-483 with seven observations from an inspection at the Exton, PA-based ProRx outsourcing facility.

latest-news-card-1
Human Drugs

Sanofi Scraps Tolebrutinib MS Filing after Phase 3 Miss

Sanofi says it will not seek FDA approval for tolebrutinib in primary progressive multiple sclerosis after the drug failed to meet its primary endpoin...

latest-news-card-1
FDA General

Restrictions on Real-World Evidence Regulatory Reviews Eased

FDA says it is removing a long-standing barrier to the use of real-world evidence in regulatory reviews by accepting such data without requiring ident...